OWD
JAZZ icon

Osborn Williams & Donohoe’s Jazz Pharmaceuticals JAZZ Stock Holding History

Osborn Williams & Donohoe’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-235
Closed -$33K – 497
2019
Q1 		$33K Buy
+235
New +$30.7K ﹤0.01% 515

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Osborn Williams & Donohoe's JAZZ Position: Q2 2019 in Review

Osborn Williams & Donohoe sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 235 shares — an estimated $33K sold.

Osborn Williams & Donohoe first reported a position in JAZZ in Q1 2019 and held it in 1 quarter. The position peaked at $33K in Q1 2019. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Osborn Williams & Donohoe reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 235 Jazz Pharmaceuticals shares in Q2 2019, an estimated $33K.
  • Osborn Williams & Donohoe first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Osborn Williams & Donohoe's Jazz Pharmaceuticals position peaked at $33K in Q1 2019.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q2 2019, filed 26 Jul 2019.